Next-generation sequencing of urine specimens: A novel platform for genomic analysis in patients with non–muscle-invasive urothelial carcinoma treated with bacille Calmette-Guérin Journal Article
| Authors: | Scott, S. N.; Ostrovnaya, I.; Lin, C. M.; Bouvier, N.; Bochner, B. H.; Iyer, G.; Solit, D.; Berger, M. F.; Lin, O. |
| Article Title: | Next-generation sequencing of urine specimens: A novel platform for genomic analysis in patients with non–muscle-invasive urothelial carcinoma treated with bacille Calmette-Guérin |
| Abstract: | BACKGROUND: Biopsies from patients with high-risk (HR) non–muscle-invasive urothelial carcinoma (NMIUC), especially flat urothelial carcinoma in situ, frequently contain scant diagnostic material or denuded mucosa only, and this precludes further extensive genomic analysis. This study evaluated the use of next-generation sequencing (NGS) analysis of urine cytology material from patients with HR NMIUC in an attempt to identify genetic alterations that might correlate with clinical features and responses to bacille Calmette-Guérin (BCG) treatment. METHODS: Forty-one cytology slides from patients with HR NMIUC treated with intravesical BCG were selected for this study. Histological confirmation was available for all cases. The specimens were subjected to NGS analysis with a customized targeted exome capture assay composed of 341 genes. RESULTS: In this cohort, genomic alterations were successfully identified in all cytology samples. Mutations were detected down to a 2% allele frequency and chromosomal rearrangements including copy number alterations and gene fusions were identified. The most frequently altered genes included telomerase reverse transcriptase (TERT), tumor protein 53 (TP53), Erb-B2 receptor tyrosine kinase 2 (ERBB2), and chromatin remodeling genes such as lysine demethylase 6A (KDM6A) and AT-rich interaction domain 1A (ARID1A). For patients with matched tumor tissue, cytology specimens revealed all mutations detected in tissue as well as additional mutations, and this suggested that urine might more effectively capture the full genetic heterogeneity of disease than an individual cystectomy. Alterations in multiple genes correlated with clinical and histopathological features, including responses to BCG treatment, flat architecture versus papillary architecture, and smoking history. CONCLUSIONS: Urine specimens can replace tissue as a substrate for NGS analysis of HR NMIUC. Several genomic alterations identified in urine specimens might be associated with histological features and clinical characteristics. Cancer Cytopathol 2017;125:416–26. © 2017 American Cancer Society. © 2017 American Cancer Society |
| Keywords: | bladder cancer; urine cytology; next-generation sequencing; bacille calmette-guérin (bcg) |
| Journal Title: | Cancer Cytopathology |
| Volume: | 125 |
| Issue: | 6 |
| ISSN: | 1934-662X |
| Publisher: | John Wiley & Sons |
| Date Published: | 2017-06-01 |
| Start Page: | 416 |
| End Page: | 426 |
| Language: | English |
| DOI: | 10.1002/cncy.21847 |
| PROVIDER: | scopus |
| PMCID: | PMC5477237 |
| PUBMED: | 28339163 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 3 July 2017 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work